Clinical and Laboratory Follow-up After Hospitalization for COVID-19 at an Italian Tertiary Care Center
Michele Spinicci(University of Florence), Daniela Bacherini(Azienda Ospedaliero-Universitaria Careggi), Laura Rasero(University of Florence), Leonardo Gori(University of Florence), Luca Livi, Andrea Matucci(Ospedale Sacro Cuore Don Calabria), Francesco Annunziato(Azienda Ospedaliero-Universitaria Careggi), Betti Giusti(Azienda Ospedaliero-Universitaria Careggi), Lorenzo Cosmi(Fraunhofer Institute for Cell Therapy and Immunology), Cecilia Defraia, Silvia Sticci, Laura Maggi, Iacopo Olivotto(Azienda Ospedaliero-Universitaria Careggi), Paola Parronchi(Azienda Ospedaliero-Universitaria Careggi), Fabio Almerigogna(University of Florence), Francesco Fattirolli(Azienda Ospedaliero-Universitaria Careggi), Luigi Tassetti, Fabrizio Giansanti(Azienda Ospedaliero-Universitaria Careggi), Chiara Zocchi(Ospedale San Donato), Alessio Mazzoni(Azienda Ospedaliero-Universitaria Careggi), Maria Vittoria Silverii, Francesco Liotta(Azienda Ospedaliero-Universitaria Careggi), Rossella Marcucci(Ospedali Riuniti San Giovanni di Dio e Ruggi d'Aragona), Lorenzo Zammarchi(Azienda Ospedaliero-Universitaria Careggi), Federico Lavorini(Azienda Ospedaliero-Universitaria Careggi), Beatrice Borchi, Luca Ciani, Niccolò Marchionni(Azienda Ospedaliero-Universitaria Careggi), Irene Campolmi(Azienda Ospedaliero-Universitaria Careggi), Marta Tilli(University of Florence), Iacopo Vellere(University of Florence), Lucia Graziani(University of Florence), Carlo Fumagalli(Azienda Ospedaliero-Universitaria Careggi), Jessica Mencarini(Azienda Ospedaliero-Universitaria Careggi), Alessandro Bartoloni(University of Florence), Lorenzo Giovannoni, Martina Donati, Alessandra Vultaggio(Azienda Ospedaliero-Universitaria Careggi)
Cited by 14
Related Papers
2023 ESC Guidelines for the management of cardiomyopathies
|European Heart Journal|2023|2.3k
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2020|1.2k
Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy
|Circulation|2014|1k
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
|European Journal of Immunology|2019|1k
Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy
|Circulation|2018|837